Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Pharma
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Novartis is mitigating a potential threat from the BIOSECURE Act. A Neurocrine drug from Takeda posted a trial win. Enhertu nears a HER2-low readout.
Angus Liu
Apr 26, 2024 5:45am
Biogen plots 30% Leqembi field force bump, omnichannel campaigns
Apr 25, 2024 6:58am
Biogen's fortunes are trending upward thanks to its new launches
Apr 24, 2024 11:24am
Leqembi launch hamstrung by physicians' 'therapeutic nihilism'
Apr 23, 2024 9:50am
Biogen CEO's 2023 pay shrank by 87%
Apr 16, 2024 1:00pm
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am